You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFlibanserin
Accession NumberDB04908
TypeSmall Molecule
GroupsApproved
DescriptionFlibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin's mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters.
Structure
Thumb
Synonyms
BIMT-17
BIMT-17-BS
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AddyiTablet, film coated100 mg/1OralSprout Pharmaceuticals, Inc.2015-08-18Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EctrisNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Flibanserin hydrochloride
ThumbNot applicableDBSALT001321
Categories
UNII37JK4STR6Z
CAS number167933-07-5
WeightAverage: 390.4021
Monoisotopic: 390.166745929
Chemical FormulaC20H21F3N4O
InChI KeyPPRRDFIXUUSXRA-UHFFFAOYSA-N
InChI
InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
IUPAC Name
1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
FC(F)(F)C1=CC(=CC=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1
Pharmacology
IndicationFor the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionFlibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 1AProteinyes
agonist
HumanP08908 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
D(4) dopamine receptorProteinyes
antagonist
HumanP21917 details
Related Articles
AbsorptionFlibanserin has an absolute oral availability of 33%.
Volume of distributionNot Available
Protein binding~98%, highly bound to proteins (mostly albumin) in serum.
Metabolism

Metabolism is primarily via CYP3A4, slightly CYP2C19. Minimal involvement of CYP1A2, CYP2B6, CYP2C8, CYP2C9 or CYP2D6. At least 35 metabolites of flibanserin are produced, 2 of which reach plasma concentrations as high as parent drug, however they are pharmacologically inactive.

Route of eliminationElimination via feces (51%) and urine (44%) following a single oral 50 mg dose of flibanserin solution.
Half life≈11 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Flibanserin is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Flibanserin.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Flibanserin.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Flibanserin.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Flibanserin.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Flibanserin.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Flibanserin.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Flibanserin.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Flibanserin.Experimental, Illicit
AlprazolamThe serum concentration of Flibanserin can be increased when it is combined with Alprazolam.Approved, Illicit, Investigational
AmiodaroneThe serum concentration of Flibanserin can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Flibanserin.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flibanserin.Approved
AmlodipineThe serum concentration of Flibanserin can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Flibanserin.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Flibanserin.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Flibanserin.Experimental
AprepitantThe serum concentration of Flibanserin can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flibanserin.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Flibanserin.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Flibanserin.Approved
AtazanavirThe serum concentration of Flibanserin can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Flibanserin can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Flibanserin can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Flibanserin.Vet Approved
AzelastineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Flibanserin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Flibanserin.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Flibanserin.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Flibanserin is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Flibanserin.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Flibanserin.Approved
BexaroteneThe serum concentration of Flibanserin can be decreased when it is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Flibanserin can be increased when it is combined with Bicalutamide.Approved
BoceprevirThe serum concentration of Flibanserin can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Flibanserin can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Flibanserin can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Flibanserin is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Flibanserin.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Flibanserin.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Flibanserin.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Flibanserin.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Flibanserin.Approved, Investigational
BuprenorphineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Flibanserin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Flibanserin.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Flibanserin.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Flibanserin.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Flibanserin.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Flibanserin.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flibanserin.Approved, Illicit, Vet Approved
CarbamazepineThe serum concentration of Flibanserin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Flibanserin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Flibanserin.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Flibanserin.Approved
CeritinibThe serum concentration of Flibanserin can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Flibanserin.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Flibanserin.Approved, Illicit, Vet Approved
ChloramphenicolThe serum concentration of Flibanserin can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Flibanserin.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Flibanserin.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flibanserin.Approved
ChlorotrianiseneThe serum concentration of Flibanserin can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Flibanserin.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Flibanserin.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flibanserin.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Flibanserin.Approved
CilostazolThe serum concentration of Flibanserin can be increased when it is combined with Cilostazol.Approved
CimetidineThe serum concentration of Flibanserin can be increased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Flibanserin.Approved, Vet Approved
CiprofloxacinThe serum concentration of Flibanserin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe risk or severity of adverse effects can be increased when Flibanserin is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Flibanserin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Flibanserin can be increased when it is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Flibanserin.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Flibanserin.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Flibanserin.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Flibanserin.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Flibanserin.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Flibanserin.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Flibanserin.Approved, Illicit
ClotrimazoleThe serum concentration of Flibanserin can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Flibanserin.Approved
CobicistatThe serum concentration of Flibanserin can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Flibanserin.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Flibanserin.Approved, Illicit
ConivaptanThe serum concentration of Flibanserin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Flibanserin can be increased when it is combined with Conjugated Equine Estrogens.Approved
CrizotinibThe serum concentration of Flibanserin can be increased when it is combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Flibanserin.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flibanserin.Approved
CyclosporineThe serum concentration of Flibanserin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Flibanserin.Approved
DabrafenibThe serum concentration of Flibanserin can be decreased when it is combined with Dabrafenib.Approved
DalfopristinThe serum concentration of Flibanserin can be increased when it is combined with Dalfopristin.Approved
DanazolThe serum concentration of Flibanserin can be increased when it is combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flibanserin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Flibanserin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Flibanserin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Flibanserin can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Flibanserin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Flibanserin can be increased when it is combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Flibanserin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Flibanserin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Flibanserin.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Flibanserin.Approved, Investigational
DesogestrelThe serum concentration of Flibanserin can be increased when it is combined with Desogestrel.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Flibanserin.Vet Approved
DexamethasoneThe serum concentration of Flibanserin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Flibanserin.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Flibanserin.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Flibanserin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Flibanserin.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Flibanserin.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Flibanserin.Approved, Illicit, Vet Approved
DienestrolThe serum concentration of Flibanserin can be increased when it is combined with Dienestrol.Approved
DienogestThe serum concentration of Flibanserin can be increased when it is combined with Dienogest.Approved
DiethylstilbestrolThe serum concentration of Flibanserin can be increased when it is combined with Diethylstilbestrol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Flibanserin.Approved, Illicit
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Flibanserin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Flibanserin.Approved, Illicit
DihydroergotamineThe serum concentration of Flibanserin can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Flibanserin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Flibanserin.Experimental, Illicit
DiltiazemThe serum concentration of Flibanserin can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Flibanserin.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Flibanserin.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Flibanserin.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Flibanserin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Flibanserin.Approved
DoxycyclineThe serum concentration of Flibanserin can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Flibanserin.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Illicit
DronedaroneThe serum concentration of Flibanserin can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Vet Approved
DrospirenoneThe serum concentration of Flibanserin can be increased when it is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Flibanserin.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Flibanserin.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Flibanserin.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Flibanserin.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Flibanserin can be decreased when it is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Flibanserin.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Flibanserin.Approved, Investigational
EnzalutamideThe serum concentration of Flibanserin can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe serum concentration of Flibanserin can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Flibanserin is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Flibanserin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Flibanserin.Approved, Illicit
EstradiolThe serum concentration of Flibanserin can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Flibanserin can be increased when it is combined with Estramustine.Approved
Estrogens, esterifiedThe serum concentration of Flibanserin can be increased when it is combined with Estrogens, esterified.Approved
Estrone sulfateThe serum concentration of Flibanserin can be increased when it is combined with Estrone sulfate.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Flibanserin.Approved
EthanolEthanol may increase the hypotensive activities of Flibanserin.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Flibanserin.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Flibanserin can be increased when it is combined with Ethinyl Estradiol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Flibanserin.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Flibanserin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Flibanserin.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Flibanserin.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Flibanserin.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Flibanserin can be increased when it is combined with Ethynodiol diacetate.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Flibanserin.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Flibanserin.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Flibanserin.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Flibanserin.Approved
EtonogestrelThe serum concentration of Flibanserin can be increased when it is combined with Etonogestrel.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Flibanserin.Illicit, Vet Approved
EtravirineThe serum concentration of Flibanserin can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Flibanserin.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Flibanserin.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Flibanserin.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Flibanserin.Approved
FluconazoleThe serum concentration of Flibanserin can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Flibanserin.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Flibanserin.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Flibanserin.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Flibanserin.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flibanserin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Flibanserin.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Flibanserin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Flibanserin.Approved
FluvoxamineThe serum concentration of Flibanserin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Flibanserin can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Flibanserin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Flibanserin can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Flibanserin.Approved, Illicit
Fusidic AcidThe serum concentration of Flibanserin can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Flibanserin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Flibanserin is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Flibanserin.Approved, Illicit
GemfibrozilThe serum concentration of Flibanserin can be increased when it is combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Flibanserin is combined with Gepirone.Investigational
GestodeneThe serum concentration of Flibanserin can be increased when it is combined with Gestodene.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Flibanserin.Approved, Illicit
Glycerol PhenylbutyrateThe serum concentration of Flibanserin can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Flibanserin.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Flibanserin.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flibanserin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Flibanserin.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Flibanserin.Approved, Illicit
HexestrolThe serum concentration of Flibanserin can be increased when it is combined with Hexestrol.Withdrawn
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Flibanserin.Approved
HydrocodoneFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Flibanserin.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
IdelalisibThe serum concentration of Flibanserin can be increased when it is combined with Idelalisib.Approved
IloperidoneThe serum concentration of Flibanserin can be increased when it is combined with Iloperidone.Approved
ImatinibThe serum concentration of Flibanserin can be increased when it is combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Flibanserin.Approved
IndalpineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Flibanserin can be increased when it is combined with Indinavir.Approved
IsavuconazoniumThe serum concentration of Flibanserin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Flibanserin.Approved, Vet Approved
IsoniazidThe serum concentration of Flibanserin can be increased when it is combined with Isoniazid.Approved
IsradipineThe serum concentration of Flibanserin can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Flibanserin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Flibanserin can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Flibanserin.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flibanserin.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Flibanserin.Approved
KetoconazoleThe serum concentration of Flibanserin can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Flibanserin.Approved, Investigational
LapatinibThe serum concentration of Flibanserin can be increased when it is combined with Lapatinib.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Flibanserin.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Flibanserin.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Flibanserin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Flibanserin.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levomilnacipran.Approved
LevonorgestrelThe serum concentration of Flibanserin can be increased when it is combined with Levonorgestrel.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Flibanserin.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Flibanserin.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Flibanserin.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Flibanserin.Illicit
LomitapideThe serum concentration of Flibanserin can be increased when it is combined with Lomitapide.Approved
LopinavirThe serum concentration of Flibanserin can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Flibanserin.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Flibanserin.Approved
LovastatinThe serum concentration of Flibanserin can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flibanserin.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Flibanserin.Investigational
LuliconazoleThe serum concentration of Flibanserin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Flibanserin can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe serum concentration of Flibanserin can be increased when it is combined with Lurasidone.Approved
LynestrenolThe serum concentration of Flibanserin can be increased when it is combined with Lynestrenol.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flibanserin.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Flibanserin.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Flibanserin.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Flibanserin can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Flibanserin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Flibanserin.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flibanserin.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flibanserin.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Flibanserin.Approved
MestranolThe serum concentration of Flibanserin can be increased when it is combined with Mestranol.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flibanserin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Flibanserin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Flibanserin.Approved, Illicit
MethallenestrilThe serum concentration of Flibanserin can be increased when it is combined with Methallenestril.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Flibanserin.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Flibanserin.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flibanserin.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Flibanserin.Approved
MethotrimeprazineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Flibanserin.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Flibanserin.Approved
MetyrosineFlibanserin may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flibanserin.Approved, Illicit
MifepristoneThe serum concentration of Flibanserin can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Flibanserin is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Investigational
MirtazapineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Flibanserin can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Flibanserin can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Flibanserin.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Flibanserin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved, Investigational
NafcillinThe serum concentration of Flibanserin can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Flibanserin.Approved
NefazodoneThe serum concentration of Flibanserin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Flibanserin can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Flibanserin can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Flibanserin can be increased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Flibanserin can be increased when it is combined with Nicardipine.Approved
NilotinibThe serum concentration of Flibanserin can be increased when it is combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Flibanserin.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Flibanserin.Approved, Vet Approved
NorelgestrominThe serum concentration of Flibanserin can be increased when it is combined with Norelgestromin.Approved
NorgestimateThe serum concentration of Flibanserin can be increased when it is combined with Norgestimate.Approved
NorgestrelThe serum concentration of Flibanserin can be increased when it is combined with Norgestrel.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Flibanserin.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Flibanserin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Flibanserin.Approved, Investigational
OlaparibThe serum concentration of Flibanserin can be increased when it is combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flibanserin.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Flibanserin.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Flibanserin.Approved, Illicit
OrphenadrineFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Flibanserin.Investigational
OsimertinibThe serum concentration of Flibanserin can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flibanserin.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Flibanserin.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Flibanserin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Flibanserin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Flibanserin.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Flibanserin can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Flibanserin.Approved
ParaldehydeFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Flibanserin can be increased when it is combined with Pazopanib.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Flibanserin.Approved, Vet Approved
PentobarbitalThe serum concentration of Flibanserin can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
PerazineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Flibanserin.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Flibanserin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Flibanserin.Approved
PhenobarbitalThe serum concentration of Flibanserin can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Flibanserin.Approved
PhenytoinThe serum concentration of Flibanserin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Flibanserin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Flibanserin.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Flibanserin.Approved
PiritramideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Flibanserin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleFlibanserin may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Flibanserin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Flibanserin.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Flibanserin.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Flibanserin.Approved
PrimidoneThe serum concentration of Flibanserin can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Flibanserin.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flibanserin.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Flibanserin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Flibanserin.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Flibanserin.Approved, Vet Approved
PropofolThe serum concentration of Flibanserin can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Flibanserin.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flibanserin.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Flibanserin.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Flibanserin.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flibanserin.Approved
QuinidineThe serum concentration of Flibanserin can be increased when it is combined with Quinidine.Approved
QuinupristinThe serum concentration of Flibanserin can be increased when it is combined with Quinupristin.Approved
RacloprideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Flibanserin.Approved, Investigational
RanolazineThe serum concentration of Flibanserin can be increased when it is combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flibanserin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Flibanserin.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Flibanserin.Approved
RifabutinThe serum concentration of Flibanserin can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Flibanserin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Flibanserin can be decreased when it is combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Flibanserin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Flibanserin can be increased when it is combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Flibanserin.Vet Approved
RopiniroleFlibanserin may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Flibanserin.Approved
RotigotineFlibanserin may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Flibanserin.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Flibanserin.Experimental
Sage 547The risk or severity of adverse effects can be increased when Flibanserin is combined with Sage 547.Investigational
SaquinavirThe serum concentration of Flibanserin can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Flibanserin.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flibanserin.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Flibanserin.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flibanserin.Approved, Vet Approved
SildenafilThe serum concentration of Flibanserin can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Flibanserin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Flibanserin can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
St. John's WortThe serum concentration of Flibanserin can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Flibanserin can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin.Approved, Investigational
SulfisoxazoleThe serum concentration of Flibanserin can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Flibanserin.Approved
SuvorexantFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Flibanserin can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
TandospironeThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tasimelteon.Approved
TelaprevirThe serum concentration of Flibanserin can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Flibanserin can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Flibanserin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Flibanserin.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Flibanserin.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Flibanserin.Investigational
ThalidomideFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Flibanserin.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Flibanserin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Flibanserin.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Flibanserin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Flibanserin.Approved
TiaprideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Flibanserin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Flibanserin can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Flibanserin.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Flibanserin.Approved
TocilizumabThe serum concentration of Flibanserin can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Flibanserin.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Flibanserin.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flibanserin.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Flibanserin.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flibanserin.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Flibanserin.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Flibanserin.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Flibanserin.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Flibanserin.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Flibanserin.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Flibanserin.Approved
Uc1010The risk or severity of adverse effects can be increased when Flibanserin is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Flibanserin.Approved, Investigational
VenlafaxineThe serum concentration of Flibanserin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Flibanserin can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Flibanserin.Approved
VoriconazoleThe serum concentration of Flibanserin can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Flibanserin.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Flibanserin.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flibanserin.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Flibanserin is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Flibanserin is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Flibanserin can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Flibanserin.Vet Approved
ZolpidemFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flibanserin.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Flibanserin.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Flibanserin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Flibanserin.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707 ]
  2. Scandroglio A, Monferini E, Borsini F: Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors. Pharmacol Res. 2001 Feb;43(2):179-83. [PubMed:11243720 ]
  3. Borsini F, Cesana R: Mechanism of action of flibanserin in the learned helplessness paradigm in rats. Eur J Pharmacol. 2001 Dec 14;433(1):81-9. [PubMed:11755137 ]
  4. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684 ]
  5. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]
  6. Stahl SM: Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015 Feb;20(1):1-6. doi: 10.1017/S1092852914000832. Epub 2015 Feb 9. [PubMed:25659981 ]
External Links
ATC CodesG02CX02
AHFS Codes
  • 28:92
PDB EntriesNot Available
FDA labelDownload (788 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9857
Caco-2 permeable-0.7652
P-glycoprotein substrateSubstrate0.6865
P-glycoprotein inhibitor IInhibitor0.8895
P-glycoprotein inhibitor IIInhibitor0.8741
Renal organic cation transporterInhibitor0.6378
CYP450 2C9 substrateNon-substrate0.7906
CYP450 2D6 substrateNon-substrate0.5905
CYP450 3A4 substrateSubstrate0.6954
CYP450 1A2 substrateInhibitor0.8379
CYP450 2C9 inhibitorNon-inhibitor0.7028
CYP450 2D6 inhibitorInhibitor0.5876
CYP450 2C19 inhibitorNon-inhibitor0.59
CYP450 3A4 inhibitorInhibitor0.7523
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9005
Ames testNon AMES toxic0.6798
CarcinogenicityNon-carcinogens0.9354
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6546 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6138
hERG inhibition (predictor II)Inhibitor0.9486
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral100 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7151103 No2003-05-092023-05-09Us
US7420057 No2002-08-012022-08-01Us
US8227471 No2003-05-092023-05-09Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.178 mg/mLALOGPS
logP3.32ALOGPS
logP3.83ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)12.91ChemAxon
pKa (Strongest Basic)7.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.82 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity103.65 m3·mol-1ChemAxon
Polarizability38.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Benzimidazole
  • Substituted aniline
  • Dialkylarylamine
  • N-alkylpiperazine
  • Aniline
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707 ]
  2. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684 ]
  3. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684 ]
  2. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707 ]
  3. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of flibanserin. CNS Drug Rev. 2002 Summer;8(2):117-42. [PubMed:12177684 ]
  2. Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R: Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003 Aug;139(7):1281-8. [PubMed:12890707 ]
  3. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Deeks ED: Flibanserin: First Global Approval. Drugs. 2015 Oct;75(15):1815-22. doi: 10.1007/s40265-015-0474-y. [PubMed:26412054 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on December 07, 2016 02:40